Dana-Farber Cancer Institute Reviewing 37 Scientific Studies for Alleged Data Falsification

Published on January 25, 2024

Boston-based Dana-Farber Cancer Institute (DFCI), an affiliate of Harvard Medical School, acknowledged on Jan. 23 that it would seek retractions for six research papers and corrections for an additional 31. The retractions and corrections come after Sholto David, a British molecular biologist, called out many of DFCI’s top brass, including CEO Dr. Laurie Glimcher and Chief Operating Officer Dr. William Hahn, alleging they had published papers that duplicated or manipulated data. The investigation comes less than a month after Harvard’s president, Claudine Gay, resigned amid pressures resulting from plagiarism allegations. Officials at DFCI have reported that the review process for some of the studies in question began over a year ago. The institute’s research integrity officer told news outlets that while not all 57 claims are being reviewed, several complaints are serious and credible enough to warrant investigation....